Actualités et vidéos - ESPERITE

The Netherlands – 5 October 2020 Voting results are set out below: Number of shares represented at the meeting: 11'070'877 Percentage of issued share capital as per the registration date: 14.33% Agenda item - Resolution # votes % votes For Against Abstain Result Agenda item 2 Approval Minutes of the Annual General Meeting of Shareholders of 8 January 2019 11'070'877 14.33% 10'346'865 2'001 722'011 Adopted Agenda item 5 Delegation to the Board of Directors of the powers to issue, and grant...

The Netherlands – 18 September 2020 Esperite N.V. (Euronext: ESP, “ Esperite ” or the “ Company ”) announces that due to sanitary constraints the Extraordinary General Meeting of Shareholders (“ EGM ”) to be held on 30 September 2020 at 14:00 CET will be organized by audio and video conference. As at the date hereof, the Company has an issued and outstanding share capital of EUR 7,724,754.80 comprising 77,247,548 ordinary shares with a nominal value of EUR 0.10 each and 31...

The Netherlands – 19 August 2020 Esperite N.V. (Euronext: ESP, “ Esperite ” or the “ Company ”) announces that it has convened its Extraordinary General Meeting of Shareholders (“ EGM ”) to be held on 30 September 2020 at 14:00 CET at Hotel NH Amsterdam Barbizon Palace, Prins Hendrikkade 59-72, 1012 AD Amsterdam, the Netherlands. On 14 April 2020, the Company was placed in bankruptcy under the Dutch Bankruptcy Act. The Board of Directors intends to enter into negotiations with the...

Pays-Bas, le 5 août 2020 - Le Conseil d'administration d'Esperite N.V. (Euronext : ESP), lors de sa réunion du 30 Juillet 2020, a pris acte du départ de Frédéric Amar de son poste de Directeur Général pour des raisons de santé. Frédéric Amar conserve son mandat d'administrateur et, à ce titre, continuera de faire bénéficier Esperite de son expertise. Le Conseil, à l'unanimité de ses membres, a décidé de coopter Hugo Brugière en qualité d'administrateur et de le nommer...

The Netherlands, August 5 2020 - The Board of Directors of Esperite N.V. (Euronext: ESP), at its meeting of 30 July, 2020, noted the departure of Frédéric Amar from his position as Chief Executive Officer for health reasons. Frédéric Amar maintains his mandate as Director and, as such, will continue to provide Esperite with the benefit of his expertise. The Board, by unanimous vote of its members, decided to appoint Hugo Brugière as a director and to appoint him as Chief Executive Officer...

Points forts de l'opération · Esperite NV sécurise un financement externe d'un montant maximum de 35 millions d'euros par le biais de placements privés d'obligations convertibles assorties de bons de souscription d'actions sur une période de 36 mois, sous réserve du respect de certaines conditions · Les bons de souscription d'actions, s'ils sont exercés, génèreront un produit supplémentaire de 35 millions d'euros sur une période de 5 ans · Un prêt relais de 150 000 euros émis...

Transaction highlights · Esperite NV secures an external financing of up to EUR 35 million through further private placements of convertible notes with share subscription warrants attached over a period of 36 months, subject to fulfillment of certain conditions · The Warrants, if exercised, are leading to an additional EUR 35 million proceeds over a period of 5 years · Bridge note of EUR 150,000 issued today · Subscription by European Small Caps Opportunities Fund, based in Australia ·...

Transaction highlights · Esperite NV secures an external financing of up to EUR 35 million through further private placements of convertible notes with share subscription warrants attached over a period of 36 months, subject to fulfillment of certain conditions · The Warrants, if exercised, are leading to an additional EUR 35 million proceeds over a period of 5 years · Bridge note of EUR 150,000 issued today · Subscription by European Small Caps Opportunities Fund, based in Australia ·...

Esperite announces its decision to oppose the Dutch Authority for the Financial Markets (AFM) who levied a fine on the company (amounting to EUR 312,500), regarding what the AFM deemed to be repeated delayed disclosures of financial figures between 2016 and 2019. Esperite will use the legal period of six weeks to elaborate a substantiated answer to the AFM. The company had on due course informed its shareholders of technical difficulties to publish on time. When, in June 2019, the Company's...

Esperite confirms that the Swiss prosecutor launched a preliminary penal investigation into the activities of its former subsidiary CryoSave after several clients and third parties have alerted the Swiss Public Health Authorities over the transport of their samples. The former Director of CryoSave, Frederic Amar who was in office from January 2016 to September 2019 is therefore also under this investigation. Esperite declares that this indictment will allow its Director, Frederic Amar to defend...

Esperite updates its shareholders on the current configuration and business of the company. Esperite has taken distance from the operative part of its activities and focus its effort on turning itself in an investment company with a focus on Health Care and High-Tech Service. The current subsidiaries of the group, Output Pharma, Genoma with Agaata are now considered as assets held for sale. Therefore, they will not be part any longer of the consolidation perimeter of the group. Esperite was the...

Esperite N.V. (Euronext: ESP, “Esperite”) announces that it has convened an Extraordinary General Meeting of Shareholders (“EGM”) to be held on 26 March 2020 at 14:00 hours CET at Immeuble le Patio, 35-37 Rue Louis Guérin, 69100 Villeurbanne, France The EGM's convocation notice, agenda and the explanatory notes to the agenda and further EGM materials can be downloaded from Esperite's website. ( www.esperite.com ) Shareholders interested in attending the EGM are invited to contact...

Samples and Database are safe Amsterdam, The Netherlands – 10 February 2020 Esperite N.V. (Euronext: ESP, “Esperite”) has noticed several articles in the news, online channels and information blogs about a hypothetical loss of umbilical cord blood samples during the transport from Belgium, Switzerland to Poland. Esperite has published since September 26th 2019 a CryoSave section on its website which describes the different steps from the transaction with the Polish partner, Myrisoph and...

ESPERITE (ESP) is not bankrupt. Amsterdam, The Netherlands – 30 October 2019 The court in Zutphen has annuled the bankruptcy of the company. Esperite and its management have worked on a restructuring plan and will present very soon its new strategy during a Extraordinary General Meeting with its shareholders. To learn more about the ESPERITE Group, [email protected] or visit the website at www.esperite.com , *** This press release contains inside information as referred to in article 7...

Amsterdam, The Netherlands – 14 October 2019 The Court in Gelderland, Netherlands, on October 8 th , 2019, has declared Esperite in bankruptcy. The board of directors of Esperite N.V. disputes the verdict and will appeal the order. Esperite N.V. will keep all interested parties informed. Esperite N.V. (Euronext: ESP, “Esperite” or “the Group”) announces To learn more about the ESPERITE Group, [email protected] or visit the website at www.esperite.com , Attachment PR - 14 October...

Esperite N.V. (ESP) : Update to the market on its Cord Blood Stem Cells Subsidiaries and activity. Amsterdam, The Netherlands – 1st October 2019 Esperite N.V. (the Group) confirmed on 22nd February 2019 the intentions of the Group to sell its Cord Blood Stem Cells activities in an transaction composed by two main elements. The Storage Agreement signed between CryoSave AG and its new Polish partner, which main advantages is to consolidate all the samples from different country in one secured...

CryoSave has maintained without compromise the high-quality processing and storage services and has handed over its whole business. Switzerland – 19 September 2019 CryoSave has since its establishment in 2000, ensured the best security for its clients and has a proven track record of professionalism and expertise in the field of stem cells banking, recognized by the medical community. CryoSave is one of the largest and longest operating stem cell banks in Europe, having stored more than...

ESPERITE NV AND MYRISOPH CAPITAL CONCLUDE A STRATEGIC AGREEMENT ON CRYO-SAVE’S FAMILY STEM CELL BANKING BUSINESS Amsterdam, the Netherlands – 27 August 2019 Esperite N.V. (Euronext: ESP) and Myrisoph Capital Inc (Myrisoph) are pleased to announce that they have concluded a strategic agreement related to Cryo-Save’s stem cell cryopreservation business. Myrisoph becomes the exclusive global licensee of the CryoSave brand for a minimum period of ten (10) years. Along with Cryo-Save’s...

ESPERITE NV (ESP) CON CRYOSAVE CONFERMA LA SICUREZZA DI TUTTI I CAMPIONI CONSERVATI E RINGRAZIA LE 260'000 FAMIGLIE PER LA LORO FIDUCIA E FIDUCIA. CryoSave ha scelto PBKM come subappaltatore appropriato per lo stoccaggio sicuro a lungo termine e intende mantenere il controllo totale delle operazioni. Amsterdam, The Netherlands – 1st July 2019 CryoSave desidera ringraziare le +260'000 famiglie già clienti per aver riposto la loro fiducia nella nostra azienda. CryoSave, fondata da 19 anni, è...

ESPERITE N.V. (ESP) publishes its half-year report. Revenues, results and consolidated equity were impacted by adverse market conditions on the stem cell business. CEO, Frédéric Amar, has converted part of his loan notes into 2.5 million shares to support the business and L1 Capital has continued financing the Company. Amsterdam, The Netherlands – 30 June 2019 Esperite NV (Euronext: ESP, “Esperite” or “the Group”) has published its financial results (unaudited) for the period of six...